Published in Cancer Weekly, February 17th, 2004
According to a study from Canada, "Primary and secondary prevention of VTE are the major roles of anti-thrombotic therapy in patients with cancer. Although the choices of pharmacological agents remain limited, LMWHs offer important advantages over traditional anticoagulants.
"For prophylaxis in the surgical setting, once-daily subcutaneous injections of LMWH are as effective and safe as multiple doses of unfractionated heparin and extending prophylaxis with LMWH beyond hospitalization can safely...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.